SCHEMBL2276155

SCHEMBL2276155

CC(=O)N(CCN(C)C)c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
CYP3A4 P08684 3/20 0.44
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
UTS2R Q9UKP6 1/20 0.42
HRH4 Q9H3N8 1/20 0.41
MLYCD O95822 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
BCL2L1 Q07817 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LIMK1 P53667 1/20 0.41
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7830726 0.84 MEN1 (0.45) MLYCDALDH1A1TSHRRAB9A
SCHEMBL20710182 0.83 HPGD (0.47) GAAUTS2RMLYCDALDH1A1POLB
SCHEMBL12449396 0.83 CYP3A4 (0.49) MMP2MMP9CYP3A4NPSR1CNR2
SCHEMBL3142097 0.82 PHLPP2 (0.46) CYP3A4NPSR1CYP1A2CYP2C19MLYCD
SCHEMBL3692845 0.82 MAPT (0.46) GAAMLYCDALDH1A1POLBL3MBTL1
SCHEMBL18457436 0.81 MEN1 (0.55) CYP3A4CYP2C19ALDH1A1TSHRL3MBTL1
SCHEMBL652110 0.81 KMT2A (0.45) CYP3A4CYP2C19MLYCDALDH1A1POLB
SCHEMBL7506151 0.79 MMP2 (0.48) MMP2MMP9CYP3A4NPSR1ALDH1A1
SCHEMBL7831241 0.79 TSPO (0.49) GAAUTS2RALDH1A1TSHRLIMK1
SCHEMBL13227080 0.79 LMNA (0.56) CYP3A4NPSR1CYP2C19UTS2RMLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994172-B2 [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism EXELIXIS, INC. (US) 2011-08-09 US disclosed
US-20080188482-A1 [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases EXELIXIS, INC. (US) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188482-A1 [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases PDPK1, MTOR, RPS6KA2 MMP2 802/4885MMP9 562/4885CYP3A4 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.